Skip to search formSkip to main contentSkip to account menu

ESHAP protocol

Known as: Cisplatin/Cytarabine/Etoposide/Methylprednisolone, ARA-C/CDDP/MePRDL/VP-16, E-SHAP 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The management of relapsed or refractory Hodgkin’s lymphoma (RR-HL) remains a challenge for hematologists and oncologists… 
Highly Cited
2008
Highly Cited
2008
The findings of this study suggest that combined therapy wih rituximab, etoposide, cytarabine, cisplatinum and methylprednisolone… 
Highly Cited
2000
Highly Cited
2000
Cyclophosphamide 1.5 g m–2 followed by granulocyte colony-stimulating factor (G-CSF) is an effective peripheral blood stem cell… 
Highly Cited
1999
Highly Cited
1999
BACKGROUND Refractory or relapsing Hodgkin's disease is associated with a poor prognosis. There is no widely accepted salvage… 
Highly Cited
1998
Highly Cited
1998
Given the generally poor outcome of advanced B cell chronic lymphocytic leukemia, experimental approaches are warranted… 
Highly Cited
1996
Highly Cited
1996
Intraocular lymphoma (IOL) is a rare form of non Hodgkin lymphoma (NHL); it has a poor prognosis and is frequently associated… 
Highly Cited
1995
Highly Cited
1995
PURPOSE We report the results of a prospective trial in which patients with relapsing non-Hodgkin's lymphomas were sequentially… 
Highly Cited
1994
Highly Cited
1994
PURPOSE This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and…